Q-omics provides the consensus-scored C1QTNF3-AMACR profile across patient tissues and cancer cell-line models. C1QTNF3-AMACR expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, C1QTNF3-AMACR is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, C1QTNF3-AMACR RNA expression shows 17,456 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, KICH, and THYM as cancer lineages where C1QTNF3-AMACR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C1QTNF3-AMACR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C1QTNF3-AMACR survival associations across molecular data types. C1QTNF3-AMACR RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C1QTNF3-AMACR RNA expression–survival associations across cancer types. High C1QTNF3-AMACR expression shows unfavorable associations in UCEC, but favorable associations in LUAD, HNSC, KIRP, UVM and SKCM. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for C1QTNF3-AMACR RNA expression.
This table summarizes C1QTNF3-AMACR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for C1QTNF3-AMACR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C1QTNF3-AMACR shows lower tumor expression in KICH and THCA and higher tumor expression in KIRC, LIHC, LUSC and BLCA. The KICH box plot shows higher C1QTNF3-AMACR RNA expression in normal versus tumor tissue (log2 FC = −0.058, t-test p < 0.001).
This table shows molecular features associated with C1QTNF3-AMACR in patient tissues and cancer cell lines. In patient samples, C1QTNF3-AMACR shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, C1QTNF3-AMACR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
